Vaccine Therapy for Patients With Stage IV Melanoma

Phase 3

• Conditions: Malignant Melanoma

• Registration Number: NCT00052156
• Lead Sponsor: CancerVax Corporation

Brief Summary

This is a Phase III study in patients with melanoma that has spread to the lymph nodes and/or a distant organ, and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2003-01-23
• Study First Submitted QC: 2003-01-23
• Study First Posted: 2003-01-24
• Status Verified: 2005-04
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 670

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (75)

Arizona Cancer Center; 🇺🇸 Tucson, Arizona, United States

Central Arkansas Veterans Healthcare System; 🇺🇸 Little Rock, Arkansas, United States

University of Arkansas for Medical Sciences; 🇺🇸 Little Rock, Arkansas, United States

Kaiser Permanente Medical Group; 🇺🇸 San Diego, California, United States

Cedars Sinai Comprehensive Cancer Center; 🇺🇸 Los Angeles, California, United States

Hoag Memorial Hospital Presbyterian; 🇺🇸 Newport Beach, California, United States

Comprehensive Cancer Center at DRMC; 🇺🇸 Palm Springs, California, United States

Sharp Hospital; 🇺🇸 San Diego, California, United States

UCSF Cancer Center and Cancer Research Institute; 🇺🇸 San Francisco, California, United States

University of Colorado Cancer Center; 🇺🇸 Aurora, Colorado, United States

Scroll for more (65 remaining)